Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Gen Investigational Oncology Medicines
“Our collaboration with Innovent reflects the power of partnerships in oncology,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “By combining innovative science with global development and commercialization expertise, we can advance more options for patients with the potential to address critical treatment gaps. This agreement reflects our deep commitment to developing medicines that enhance and extend the lives of people living with cancer.”
Share:
More News
“Orphan Drug Designation for SOT106 underscores both the urgent need for new treatment options in osteosarcoma and the strength of our ADC platform,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. “Osteosarcoma is a devastating disease that has seen little therapeutic innovation over the past four decades. Treatment
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two